1.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02530, 10-182-B, UCCRC-10-182-B, CDR0000685236, N01CM00071, 8317, NCT01208051
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00198, MC057H, CDR0000588044, N01CM00099, MAYO-MC057H, 7627, NCT00625846
|
|
3.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 802861, UPCC 03305, NCT00654238
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-049, NCT00936858
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VB-111-103, NCT01229865
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 89 Sponsor: Other Protocol IDs: UPCC 19309, 812004, NCT01263951
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1777-09, NCT01270321
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00554, OSU 12154, N01CM00070, NCT01811212
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200066-006, NCT01390818
|
|
10.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1162, NA_00048646, NCT01438554
|
|
11.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200064-001, NCT01453387
|
|
12.
|
Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-087, NCT01412762
|